Different fusion genes of BCR-ABL1 are all leukemogenic for acute lymphoblastic leukemia or chronic myeloid leukemia (CML). According to results published in Leukemia, the particular transcripts present in patients with CML are correlated with sex and age and are not constant worldwide. This study systematically assessed the frequency of these leukemogenic fusion genes in patients…
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Propensity score analysis showed that patients in the inotuzumab ozogamicin arm experienced significantly longer event-free and overall survival.
What is the role of the clinician in managing financial toxicity?
Advances in treatment options for acute myeloid leukemia may replace currently accepted induction regimens as the standard of care.
High risk for tumor lysis syndrome and creatinine clearance below 80 mL/min were associated with tumor lysis syndrome development.
The FDA has expanded the indication for Tibsovo to include treatment of newly diagnosed acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Bruce Levine, PhD, explains why targeting multiple antigens simultaneously may be the most promising approach for adoptive cell therapies such as CAR-T.
Researchers assessed 13,276 patients with chronic myeloid leukemia to characterize the incidence and types of second malignancies in this patient population.
Patients enrolled in a phase 1 trial receiving ibrutinib demonstrated augmented ex vivo CAR T-cell expansion.
Your patients may have questions about leukemia. Help them better understand the condition by sharing this article with them.
Patients carrying the -21M variant of HLA-B demonstrated more favorable clinical outcomes than patients carrying the -21T variant.
In this review, researchers discussed strategies for identifying and treating infection in patients undergoing intensive chemotherapy.
The presence of measurable residual disease may be a reliable predictor of relapse in patients with acute myeloid leukemia.
The combination of antithrombin activity and fibrinogen levels demonstrated optimal accuracy in detecting subtherapeutic L-asparaginase levels.
Relapse risk increased with cumulative granulocyte colony-stimulating factor dosage but appeared to level out at approximately 75 mg/kg to 100 mg/kg.
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
Variability in minimal residual disease measurement techniques inhibits the ability to compare data across laboratories and clinical trials.
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
Patients with rapid early response demonstrated increased event-free and overall survival when receiving augmented postinduction intensification regimens.
With advances in cancer research and treatments, patients with acute lymphoblastic leukemia (ALL) can enjoy longer lives and treatment can continue long after initial hospital admission and into the outpatient setting.1,2 Parents of children with leukemia often find themselves serving as direct caregivers for their children, an important role that may require them to receive…
Specific cytogenetic abnormalities are associated with patient outcomes after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) and may have prognostic value, according to a study published in Leukemia. A multinational research team conducted a retrospective analysis of clinical outcomes of patients with AML undergoing allogeneic HSCT while taking into account recurring…
Discontinuing antibacterial therapy in neutropenic patients with acute myeloid leukemia did not lead to excessive mortality or severe infections.
CAR T therapy has emerged in recent years as a feasible treatment for patients with chronic lymphocytic leukemia, but there are still many unanswered questions.
An expert panel from the European LeukemiaNet discussed optimal treatment strategies for patients with acute promyelocytic leukemia.
Researchers classified 49 single-agent and 13 multiple-agent chemotherapy regimens by severity of emetogenicity.
Immune checkpoint inhibitor therapy is associated with improved outcomes but it may also lead to serious adverse effects.
There is a pressing need to develop novel therapeutic strategies for patients with myelodysplastic syndrome who are ineligible for transplantation.
Researchers measured levels of glucagon-like peptide-1 and C-reactive protein to determine their value as predictive biomarkers of toxicity.
GVHD prophylaxis including anti-T-lymphocyte globulin was associated with improved survival and quality of life.
Additionally, hyperferritinemia both before and after transplant was found to have negative prognostic value.
Treating young adults with acute lymphoblastic leukemia with a pediatric regimen may lead to improved overall, event-free, and disease-free survival.
Safety and efficacy did not differ significantly between 2 decitabine treatment schedules for acute myeloid leukemia.
There are currently limited data to inform an optimal treatment strategy for cytokine release syndrome, a common complication of CAR T therapy.
Over half of patients receiving azacitidine maintenance achieved protocol completion, supporting the feasibility of this therapeutic approach.
The identification of 8 new subtypes of B progenitor acute lymphoblastic leukemia may guide the diagnosis and development of more effective targeted therapies.
Researchers found some immunobiological profiles specific to patients with acute lymphoblastic leukemia.
Researchers assessed the influence of cyclophosphamide plus etoposide on disease-free survival in patients with B-cell acute lymphoblastic leukemia.
Venetoclax and hypomethylating agents, which both demonstrate single agent activity in acute myeloid leukemia, appear to be more effective when used together.
Minimal residual disease from peripheral blood, which is easier to obtain than bone marrow, was found to correlate with some clinical outcomes.
Nonwhite race, poor acute phase nausea control, and treatment with cisplatin were all associated with higher self-reported nausea severity scores.
Hematology Advisor asked Prithviraj Bose, MD, to discuss the latest research on treatment options for CLL presented at the ASH 2018 Annual Meeting.
Patients receiving ponatinib in combination with other therapeutic agents appeared to achieve sustained responses and long-term remission.
The expanded approval was supported by data from the Phase 2 multicenter, single-arm CA180-372 study (NCT01460160) which included 78 pediatric patients with newly diagnosed B-cell precursor Ph+ ALL.
Internal tandem duplications in FLT3 and mutations in CEBPA were independently prognostic of overall survival in patients with acute myeloid leukemia.
Results of a study on the influence of induction chemotherapy on transplant outcomes for patients with acute myeloid leukemia.
Results of a phase 3 trial of efficacy that used progression-free survival as its primary endpoint.
Measurable residual disease status can inform treatment for patients with ALL, but the optimal methods for assessment and interpretation are unclear.